Cantor Fitzgerald Analysts Give Horizon Pharma PLC (HZNP) a $17.00 Price Target
Cantor Fitzgerald set a $17.00 price objective on Horizon Pharma PLC (NASDAQ:HZNP) in a research report sent to investors on Thursday. The firm currently has a buy rating on the biopharmaceutical company’s stock.
Several other research analysts have also issued reports on the company. Citigroup Inc. decreased their target price on Horizon Pharma PLC from $20.00 to $13.00 and set a buy rating for the company in a research report on Tuesday, May 9th. BMO Capital Markets reissued a buy rating and issued a $17.00 target price (down previously from $24.00) on shares of Horizon Pharma PLC in a research report on Tuesday, May 9th. Jefferies Group LLC set a $14.00 target price on Horizon Pharma PLC and gave the stock a buy rating in a research report on Tuesday, May 9th. BidaskClub raised Horizon Pharma PLC from a hold rating to a buy rating in a research report on Saturday, June 24th. Finally, ValuEngine lowered Horizon Pharma PLC from a buy rating to a hold rating in a research report on Friday, June 2nd. Five equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of Buy and an average price target of $19.46.
Shares of Horizon Pharma PLC (NASDAQ:HZNP) opened at 13.31 on Thursday. The firm has a 50-day moving average price of $12.54 and a 200-day moving average price of $13.53. Horizon Pharma PLC has a one year low of $9.45 and a one year high of $23.24. The company’s market capitalization is $2.17 billion.
Horizon Pharma PLC (NASDAQ:HZNP) last announced its earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.29. Horizon Pharma PLC had a positive return on equity of 22.85% and a negative net margin of 42.40%. The firm had revenue of $289.51 million during the quarter, compared to analyst estimates of $237.01 million. During the same quarter in the prior year, the company earned $0.56 EPS. The business’s revenue was up 12.5% compared to the same quarter last year. Equities analysts forecast that Horizon Pharma PLC will post $1.07 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This story was reported by Daily Political and is owned by of Daily Political. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/08/21/cantor-fitzgerald-analysts-give-horizon-pharma-plc-hznp-a-17-00-price-target.html.
Horizon Pharma PLC declared that its board has authorized a share buyback plan on Monday, May 8th that authorizes the company to buyback 1,000% of shares. This buyback authorization authorizes the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares buyback plans are generally an indication that the company’s leadership believes its shares are undervalued.
A number of hedge funds and other institutional investors have recently bought and sold shares of HZNP. BlackRock Inc. increased its stake in shares of Horizon Pharma PLC by 68,479.5% in the first quarter. BlackRock Inc. now owns 13,261,212 shares of the biopharmaceutical company’s stock valued at $196,001,000 after buying an additional 13,241,875 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Horizon Pharma PLC by 119.4% in the second quarter. Dimensional Fund Advisors LP now owns 6,265,608 shares of the biopharmaceutical company’s stock valued at $74,373,000 after buying an additional 3,409,411 shares in the last quarter. William Blair Investment Management LLC acquired a new stake in shares of Horizon Pharma PLC during the second quarter valued at approximately $23,557,000. Balyasny Asset Management LLC acquired a new stake in shares of Horizon Pharma PLC during the second quarter valued at approximately $13,958,000. Finally, Highbridge Capital Management LLC increased its stake in shares of Horizon Pharma PLC by 128.2% in the first quarter. Highbridge Capital Management LLC now owns 1,545,169 shares of the biopharmaceutical company’s stock valued at $22,837,000 after buying an additional 867,927 shares in the last quarter. 83.75% of the stock is owned by institutional investors.
Horizon Pharma PLC Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.